Cargando…
Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity
INTRODUCTION: The regulation of extracellular proteolytic activity via the plasminogen activation system is complex, involving numerous activators, inhibitors, and receptors. Previous studies on monocytic and colon cell lines suggest that plasmin pre-treatment can increase plasminogen binding, allow...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1851380/ https://www.ncbi.nlm.nih.gov/pubmed/17257442 http://dx.doi.org/10.1186/bcr1647 |
_version_ | 1782132962319400960 |
---|---|
author | Stillfried, Gillian E Saunders, Darren N Ranson, Marie |
author_facet | Stillfried, Gillian E Saunders, Darren N Ranson, Marie |
author_sort | Stillfried, Gillian E |
collection | PubMed |
description | INTRODUCTION: The regulation of extracellular proteolytic activity via the plasminogen activation system is complex, involving numerous activators, inhibitors, and receptors. Previous studies on monocytic and colon cell lines suggest that plasmin pre-treatment can increase plasminogen binding, allowing the active enzyme to generate binding sites for its precursor. Other studies have shown the importance of pre-formed receptors such as annexin II heterotetramer. However, few studies have used techniques that exclusively characterise cell-surface events and these mechanisms have not been investigated at the breast cancer cell surface. METHODS: We have studied plasminogen binding to MCF-7 in which urokinase plasminogen activator receptor (uPAR) levels were upregulated by PMA (12-O-tetradecanoylphorbol-13-acetate) stimulation, allowing flexible and transient modulation of cell-surface uPA. Similar experiments were also performed using MDA-MB-231 cells, which overexpress uPAR/uPA endogenously. Using techniques that preserve cell integrity, we characterise the role of uPA as both a plasminogen receptor and activator and quantify the relative contribution of pre-formed and cryptic plasminogen receptors to plasminogen binding. RESULTS: Cell-surface plasminogen binding was significantly enhanced in the presence of elevated levels of uPA in an activity-dependent manner and was greatly attenuated in the presence of the plasmin inhibitor aprotinin. Pre-formed receptors were also found to contribute to increased plasminogen binding after PMA stimulation and to co-localise with uPA/uPAR and plasminogen. Nevertheless, a relatively modest increase in plasminogen-binding capacity coupled with an increase in uPA led to a dramatic increase in the proteolytic capacity of these cells. CONCLUSION: We show that the majority of lysine-dependent plasminogen binding to breast cancer cells is ultimately regulated by plasmin activity and is dependent on the presence of significant levels of active uPA. The existence of a proteolytic positive feedback loop in plasminogen activation has profound implications for the ability of breast cancer cells expressing high amounts of uPA to accumulate a large proteolytic capacity at the cell surface, thereby conferring invasive potential. |
format | Text |
id | pubmed-1851380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-18513802007-04-12 Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity Stillfried, Gillian E Saunders, Darren N Ranson, Marie Breast Cancer Res Research Article INTRODUCTION: The regulation of extracellular proteolytic activity via the plasminogen activation system is complex, involving numerous activators, inhibitors, and receptors. Previous studies on monocytic and colon cell lines suggest that plasmin pre-treatment can increase plasminogen binding, allowing the active enzyme to generate binding sites for its precursor. Other studies have shown the importance of pre-formed receptors such as annexin II heterotetramer. However, few studies have used techniques that exclusively characterise cell-surface events and these mechanisms have not been investigated at the breast cancer cell surface. METHODS: We have studied plasminogen binding to MCF-7 in which urokinase plasminogen activator receptor (uPAR) levels were upregulated by PMA (12-O-tetradecanoylphorbol-13-acetate) stimulation, allowing flexible and transient modulation of cell-surface uPA. Similar experiments were also performed using MDA-MB-231 cells, which overexpress uPAR/uPA endogenously. Using techniques that preserve cell integrity, we characterise the role of uPA as both a plasminogen receptor and activator and quantify the relative contribution of pre-formed and cryptic plasminogen receptors to plasminogen binding. RESULTS: Cell-surface plasminogen binding was significantly enhanced in the presence of elevated levels of uPA in an activity-dependent manner and was greatly attenuated in the presence of the plasmin inhibitor aprotinin. Pre-formed receptors were also found to contribute to increased plasminogen binding after PMA stimulation and to co-localise with uPA/uPAR and plasminogen. Nevertheless, a relatively modest increase in plasminogen-binding capacity coupled with an increase in uPA led to a dramatic increase in the proteolytic capacity of these cells. CONCLUSION: We show that the majority of lysine-dependent plasminogen binding to breast cancer cells is ultimately regulated by plasmin activity and is dependent on the presence of significant levels of active uPA. The existence of a proteolytic positive feedback loop in plasminogen activation has profound implications for the ability of breast cancer cells expressing high amounts of uPA to accumulate a large proteolytic capacity at the cell surface, thereby conferring invasive potential. BioMed Central 2007 2007-01-28 /pmc/articles/PMC1851380/ /pubmed/17257442 http://dx.doi.org/10.1186/bcr1647 Text en Copyright © 2007 Stillfried et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Stillfried, Gillian E Saunders, Darren N Ranson, Marie Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity |
title | Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity |
title_full | Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity |
title_fullStr | Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity |
title_full_unstemmed | Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity |
title_short | Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity |
title_sort | plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1851380/ https://www.ncbi.nlm.nih.gov/pubmed/17257442 http://dx.doi.org/10.1186/bcr1647 |
work_keys_str_mv | AT stillfriedgilliane plasminogenbindingandactivationatthebreastcancercellsurfacetheintegralroleofurokinaseactivity AT saundersdarrenn plasminogenbindingandactivationatthebreastcancercellsurfacetheintegralroleofurokinaseactivity AT ransonmarie plasminogenbindingandactivationatthebreastcancercellsurfacetheintegralroleofurokinaseactivity |